| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vir Biotechnology Inc. | Xevudy (sotrovimab/VIR-7831) - (COMET-PEAK) | COVID-19 | Phase 2 | Trial Discontinued | Intravenous | COVID-19 |
| Vir Biotechnology Inc. | Bebtelovimab (LY-CoV1404) and Sotrovimab (VIR-7831 / GSK4182136) - (BLAZE-4) | COVID-19 antibody | Phase 2 | Trial Completed | Intravenous | COVID-19 |
| Vir Biotechnology Inc. | BRII-835 (VIR-2218) and BRII-179 (VBI-2601) | Hepatitis B | Phase 2 | Data Released | Subcutaneous | Antiviral |
| Vir Biotechnology Inc. | BRII-835 (VIR-2218) and BRII-179 (VBI-2601) | Hepatitis B | Phase 2 | Data Released | Subcutaneous | Antiviral |
| Vir Biotechnology Inc. | VIR-2218 and VIR-3434 - (STRIVE/THRIVE) | Hepatitis B virus (HBV) | Phase 2 | Ongoing | Subcutaneous | Antiviral |
| Vir Biotechnology Inc. | VIR-2218 with selgantolimod + nivolumab | Hepatitis B virus (HBV) | Phase 2 | Ongoing | subcutaneous oral intravenous | Antiviral |
| Vir Biotechnology Inc. | VIR-2482 - (PENINSULA) | Influenza | Phase 2 | Data Released | Intramuscular | Antiviral |
| Viracta Therapeutics Inc. | Nanatinostat - (NAVAL-1) | Epstein Barr Virus-associated cancers | Phase 2 | Trial Discontinued | Oral | Oncology |